Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleHigh-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs.
Author(s)Milloy MJ, Marshall B, Kerr T, Richardson L, Hogg R, Guillemi S, Montaner JS, Wood E.
Journal, Volume, IssueDrug Alcohol Rev 2015;34(2):135-40.
Major outcome(s)At least daily cannabis use was associated with significant lower plasma HIV viral loads.

INTRODUCTION AND AIMS: Cannabis use is common among people who are living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS). While there is growing pre-clinical evidence of the immunomodulatory and anti-viral effects of cannabinoids, their possible effects on HIV disease parameters in humans are largely unknown. Thus, we sought to investigate the possible effects of cannabis use on plasma HIV-1 RNA viral loads (pVLs) among recently seroconverted illicit drug users.
DESIGN AND METHODS: We used data from two linked longitudinal observational cohorts of people who use injection drugs. Using multivariable linear mixed-effects modelling, we analysed the relationship between pVL and high-intensity cannabis use among participants who seroconverted following recruitment.
RESULTS: Between May 1996 and March 2012, 88 individuals seroconverted after recruitment and were included in these analyses. Median pVL in the first 365 days among all seroconverters was 4.66 log10 c mL(-1) . In a multivariable model, at least daily cannabis use was associated with 0.51 log10 c mL(-1) lower pVL (β = -0.51, standard error = 0.170, P value = 0.003).
DISCUSSION AND CONCLUSIONS: Consistent with the findings from recent in vitro and in vivo studies, including one conducted among lentiviral-infected primates, we observed a strong association between cannabis use and lower pVL following seroconversion among illicit drug-using participants. Our findings support the further investigation of the immunomodulatory or antiviral effects of cannabinoids among individuals living with HIV/AIDS.

Duration (days)
Participants88 patients with HIV
DesignOpen study
Type of publicationMedical journal
Address of author(s)British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada

[Back to Overview]  [IACM Homepage]